The phase 1 study enrolled 40 patients with advanced AML, and showed that doses ≥3.0 mg/kg resulted in complete saturation and down-regulation of CD123 and abolition of ex vivo proliferative responsiveness to IL-3, thus indicating an adequate blockade of IL-3 signaling. Here, IL3 is linked to acute myeloid leukemia.